Judy Mohr, PhD, helps companies maximize product protection and intellectual property (IP) value by focusing on the business goals of the company and designing a patent portfolio to meet those objectives. Her practice encompasses US and non-US patent procurement, post-grant proceedings (including reexamination and inter partes review), IP due diligence on the investor side and the company side, negotiation of agreements, and development of IP strategies. She assists companies in the pharmaceutical, medical diagnostics, medical device, and gas and liquid separations industries.
Drawing on her education in biology, chemistry and chemical engineering, and her decade of industrial experience as an engineer in the polymer and pharmaceutical formulation fields, Judy provides a unique technical background that allows her to quickly assess patent portfolios and provide strategic advice. This is a key advantage in the implementation of patent strategies for pharmaceutical companies, as she is able to understand and communicate the technology to the patent examiners. Judy has worked with companies to develop patent portfolios in the pharmaceutical, drug delivery, diagnostics and water clean-up fields.
Judy has experience counseling emerging and mature life science companies in a broad range of matters, including patentability assessments, freedom to operate analyses, infringement/non-infringement evaluations, and IP due diligence in licensing transactions, financings, mergers and acquisitions. Judy frequently advises her pharmaceutical clients on topics related to Food and Drug Administration (FDA) Orange Book listings and the Hatch-Waxman Act. She also works with the IP litigators and assists clients in patent litigation matters.
Judy earned her doctoral degree in chemical engineering, with a focus in polymer properties and small molecule transport through polymer films, and her bachelor’s degree in biology.
Manages the patent portfolio for Quidel Corporation (NASDAQ: QDEL), a medical manufacturing and diagnostic testing company, as well as assisting in diligence for corporate transactions
Provides strategic patent advice and handles the patent estate for Corium International, Inc. (NASDAQ: CORI), a leader in design and manufacture of polymer film products for drug delivery and of microneedle arrays for delivery of therapeutics
Serves as IP Counsel to Heron Therapeutics, Inc. to manage its patent portfolio and advise on patent-related regulatory matters
Serves as IP Counsel to advise on patent strategy and handle patent application preparation and worldwide filings for many start-up companies, including KAI Pharmaceuticals (acquired by AMGEN), Hallux Inc., and Delpor
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.